Moderna Plans US Application Submission For COVID-19 Omicron Adapted Booster ‘Very Soon’
Moderna Inc (NASDAQ:MRNA) plans to file data with the FDA very soon, seeking approval for a booster shot targeting…
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
FDA Approves Abbott’s New Spinal Cord Stimulation Device For Pain
The FDA has approved Abbott Laboratories (NYSE:ABT) new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation…
Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial
The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized…
Bristol Myers Squibb Secures Canadian Regulatory Nod For Lung Cancer Candidate In Neoadjuvant Setting
Health Canada announced approval for Bristol Myers Squibb’s (NASDAQ: BMY) OPDIVO (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles in adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setti
This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
Mizuho initiated coverage on Ocugen Inc (NASDAQ:OCGN) with a Buy rating and a price target of $5, reflecting an upside of almost…
Medtronic Q1 Earnings Within Expectation, Sees Higher Currency Headwind On FY23 Sales
Medtronic Plc’s (NYSE:MDT) Q1 FY23 sales of $7.37 billion decreased 8% Y/Y on a reported basis and 4% organically, beating the…
Owl Creek Urges Cano Health Board To Consider Potential Sale
Owl Creek Asset Management L.P. sent a letter to Cano Health Inc (NYSE: CANO) board
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.
Merck Gets FDA Fast Track Status For Chronic Kidney Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE: MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD).